Implementing Modernized Eligibility Criteria in US National Cancer Institute Clinical Trials.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
14 11 2022
14 11 2022
Historique:
accepted:
03
06
2022
received:
19
04
2022
revised:
19
05
2022
pubmed:
2
9
2022
medline:
18
11
2022
entrez:
1
9
2022
Statut:
ppublish
Résumé
In 2018, the Cancer Therapy Evaluation Program (CTEP) at the US National Cancer Institute published new protocol template language that focused on organ function and prior and concurrent cancers in an effort to modernize eligibility criteria for cancer treatment trials. We conducted an analysis of CTEP-supported trials to evaluate the uptake and incorporation of the new language. The analysis included evaluation of 122 protocols approved in the years 2018-2020 for inclusion of the modernized eligibility criteria and consistency with new protocol template language related to 7 major eligibility criteria. These were cardiac function, liver function, kidney function, HIV status, prior and/or concurrent malignancies, treated and/or stable brain metastasis, and new and/or progressive brain metastases. Overall, CTEP trials evaluated in this period demonstrated that eligibility criteria were implemented to a relatively high degree ranging from a low of 54.1% for prior and/or concurrent malignancies to a high of 93.4% for eligibility criteria related to HIV infection. The findings demonstrate that modernized eligibility criteria can be successfully implemented but that consistent implementation requires sustained focused effort. As a result of these findings, CTEP began a new initiative in January 2022 that incorporates a specific review of eligibility criteria for new protocols to promote and improve consistency with the modernization effort.
Identifiants
pubmed: 36047830
pii: 6680187
doi: 10.1093/jnci/djac152
pmc: PMC9664179
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1437-1440Commentaires et corrections
Type : CommentIn
Informations de copyright
Published by Oxford University Press 2022.
Références
JAMA Oncol. 2019 Mar 1;5(3):326-333
pubmed: 30629092
J Clin Oncol. 2017 Nov 20;35(33):3737-3744
pubmed: 28968170
Clin Cancer Res. 2021 May 1;27(9):2394-2399
pubmed: 33563632
J Clin Oncol. 2017 Nov 20;35(33):3745-3752
pubmed: 28968168
JAMA Oncol. 2019 Apr 01;5(4):497-505
pubmed: 30653226
JCO Oncol Pract. 2021 Jul;17(7):e999-e1011
pubmed: 33970688
N Engl J Med. 2017 Apr 20;376(16):1504-1505
pubmed: 28423289
Oncologist. 2019 Jan;24(1):96-102
pubmed: 30413668
JAMA. 2019 Feb 5;321(5):447-448
pubmed: 30673081
Biol Blood Marrow Transplant. 2019 Nov;25(11):2160-2166
pubmed: 31279752
JAMA Netw Open. 2020 Dec 1;3(12):e2027110
pubmed: 33258905
Clin Cancer Res. 2016 Nov 15;22(22):5408-5416
pubmed: 27401246
J Clin Oncol. 2015 Sep 1;33(25):2753-62
pubmed: 26014291
Blood. 2016 Aug 25;128(8):1050-8
pubmed: 27297790